Tamiflu - Oseltamivir Personal Stockpiling

Influenza pandemics have occurred over the past few centuries at intervals of between 10 and 40 years, resulting in high morbidity and mortality rates, as well as significant economic impacts. Considering the uncertainties regarding the origin, timing, and virulence of future influenza strains, planning strategies for an effective response have become a chief priority of global public health efforts.

Image Credit: Photographee.eu / Shutterstock.com

Many countries started to stockpile antiviral drugs such as oseltamivir, which is more commonly known under the brand name Tamiflu, prior to the emergence of influenza A as an essential strategy for pandemic response before a new vaccine could be widely distributed. This type of approach might substantially reduce morbidity, hospitalizations, and mortality rates. In parallel to that, stockpiling for personal usage has also gained momentum.

Government vs. personal stockpiling

Pandemic stockpiling of oseltamivir is considered to be a cost-saving measure to the economy over a wide array of treatment stratagems. Furthermore, this practice can also be cost-saving to the healthcare system directly, particularly if the drug use is limited for patients at high risk. A favorable cost-benefit ratio can also be achieved if the stockpiled drug is administered either solely as a therapeutic approach, or as short-term prophylaxis for exposed individuals.

In the United States, oseltamivir and other antiviral drug stockpiles have been established at the Federal level. Following suit, many states throughout the U.S. have also established their own stockpiles. The federal government of the U.S. also encourages employers to consider stockpiling oseltamivir for use during an influenza pandemic as part of a comprehensive tactic.

The research suggests that, in order to reduce the risk of a subsequent wave of infections with a theoretical novel influenza virus that is similar to the one that caused the 1918 pandemic, pandemic plans should consider stockpiling oseltamivir and other antiviral drugs with a minimum capacity of 20% (relative to the population size).

Other analyses suggest that treatment with oseltamivir is always beneficial when compared to no action. The optimal treatment stockpile is between 40% and 60%; 40% maximizes economic benefits, whereas 60% maximizes treatment benefits.

Personal stockpiling of oseltamivir has also become widespread during this century. In the fall of 2005, for example, there were many reports of personal stockpiling of oseltamivir for use during a potential future outbreak of the H5N1 influenza virus infection (i.e. avian influenza). This increase in personal stockpiling was directly related to the increased media coverage of the potential for a worldwide pandemic.

Preparing for an Influenza Pandemic, A CDC Perspective

Controversies of personal stockpiling

Even though stockpiling may be useful in specific contexts, panicked and disorganized personal stockpiling of oseltamivir and other antivirals could reduce the availability of drugs for individuals with active infection. Additionally, personal stockpiling can also impede the strategic use of a limited drug supply when it is needed.

Greater pessimism regarding the probability of being affected by influenza is encountered among those likely to stockpile. Furthermore, differences that lead to personal stockpiling reflect individuals’ personalities and their degree of apprehension about influenza, rather than differences in their basic knowledge.

The potential ramifications of self-medication with this drug include the propagation of oseltamivir resistance, unwarranted risk of adverse events, as well as suboptimal care for individuals who should receive a more extensive clinical evaluation.

Given the nature of their specialty, infectious disease physicians are often asked to prescribe oseltamivir for personal stockpiles more than the typical provider. Therefore, educational campaigns about the appropriate use of antiviral medications that target patients during seasonal epidemics and pandemics may reduce inappropriate requests for this and other drugs.

References

Last Updated: May 18, 2021

Dr. Tomislav Meštrović

Written by

Dr. Tomislav Meštrović

Dr. Tomislav Meštrović is a medical doctor (MD) with a Ph.D. in biomedical and health sciences, specialist in the field of clinical microbiology, and an Assistant Professor at Croatia's youngest university - University North. In addition to his interest in clinical, research and lecturing activities, his immense passion for medical writing and scientific communication goes back to his student days. He enjoys contributing back to the community. In his spare time, Tomislav is a movie buff and an avid traveler.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Meštrović, Tomislav. (2021, May 18). Tamiflu - Oseltamivir Personal Stockpiling. News-Medical. Retrieved on August 04, 2021 from https://www.news-medical.net/health/Tamiflu-Oseltamivir-Personal-Stockpiling.aspx.

  • MLA

    Meštrović, Tomislav. "Tamiflu - Oseltamivir Personal Stockpiling". News-Medical. 04 August 2021. <https://www.news-medical.net/health/Tamiflu-Oseltamivir-Personal-Stockpiling.aspx>.

  • Chicago

    Meštrović, Tomislav. "Tamiflu - Oseltamivir Personal Stockpiling". News-Medical. https://www.news-medical.net/health/Tamiflu-Oseltamivir-Personal-Stockpiling.aspx. (accessed August 04, 2021).

  • Harvard

    Meštrović, Tomislav. 2021. Tamiflu - Oseltamivir Personal Stockpiling. News-Medical, viewed 04 August 2021, https://www.news-medical.net/health/Tamiflu-Oseltamivir-Personal-Stockpiling.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.